References
- Bast RC, Badgwell D, Lu Z, et al (2005). New tumor markers: CA125 and beyond. Int J Gynecol Cancer, 3 274-81.
- Bruchim I, Ben-harim Z, Piura E, Tepper R, Fishman A (2013). Preoperative clinical and radiological features of metastatic ovarian tumors. Arch Gynecol Obstet, 288, 615-9. https://doi.org/10.1007/s00404-013-2776-1
- Dodge JE, Covens AL, Lacchetti C, et al (2012). Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol, 126, 157-66. https://doi.org/10.1016/j.ygyno.2012.03.048
- Geomini P, Kruitwagen R, Bremer GL, Cnossen J, Mol BW (2009). The accuracy of risk scores in predicting ovarian malignancy: a systematic review. Obstet Gynecol, 113, 384-94. https://doi.org/10.1097/AOG.0b013e318195ad17
- Jacob F, Meier M, Caduff R, et al (2011). No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting. Gynecol Oncol, 121, 487-91. https://doi.org/10.1016/j.ygyno.2011.02.022
- Jacobs I, Oram D, Fairbanks J, et al (1990). A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol, 97, 922-9. https://doi.org/10.1111/j.1471-0528.1990.tb02448.x
- Jelovac D, Armstrong DK(2011). Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin, 61, 183-203. https://doi.org/10.3322/caac.20113
- Bian J, Li B, Kou XJ, Liu T-Z, Ming L (2013). Clinical Significance of combined detection of serum tumor markers in diagnosis of patients with ovarian cancer. Asian Pac J Cancer Prev, 14, 6241-3 https://doi.org/10.7314/APJCP.2013.14.11.6241
- Kawai M, Kano T, Kikkawa F, et al (1992). Transvaginal doppler ultrasound with color flow imaging in the diagnosis of ovarian cancer. Obstet Gynecol, 79, 163-7.
- Li L, Xu Y, Yu C-X (2013). Proteomic analysis of serum of women with elevated ca-125 to differentiate malignant from benign ovarian tumors. Asian Pac J Cancer Prev, 13, 3265-70 https://doi.org/10.7314/APJCP.2012.13.7.3265
- Menon U, Gentry-Maharaj A, Hallett R, et al (2009). Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK collaborative Trial of ovarian cancer screening (UKCTOCS). The Lancet Oncology, 10, 327-40. https://doi.org/10.1016/S1470-2045(09)70026-9
- Rafii A, Halabi NM, Malek JA (2012). High-prevalence and broad spectrum of cell adhesion and extracellular matrix gene pathway mutations in epithelial ovarian cancer. J Clin Bioinforma, 2, 15. https://doi.org/10.1186/2043-9113-2-15
- Stashwick C, Post MD, Arruda JS, et al (2011). Surgical risk score predicts suboptimal debulking or a major perioperative complication in patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer. Int J Gynecol Cancer, 21, 1422-7. https://doi.org/10.1097/IGC.0b013e31822c7704
- Tingulstad S, Hagen B, Skjeldestad FE, et al (1996). Evaluation of a risk of malignancy index based on serum CA125, ultrasound findings and menopausal status in the preoperative diagnosis of pelvic masses. Br J Obstet Gynaecol, 103, 826-31. https://doi.org/10.1111/j.1471-0528.1996.tb09882.x
- Tingulstad S, Hagen B, Skjeldestad FE, et al (1999). The riskof- malignancy index to evaluate potential ovarian cancers in local hospitals. Obstet Gynecol, 93, 448-52. https://doi.org/10.1016/S0029-7844(98)00433-5
- Van trappen PO, Rufford BD, Mills TD, et al (2007). Differential diagnosis of adnexal masses: risk of malignancy index, ultrasonography, magnetic resonance imaging, and radioimmunoscintigraphy. Int J Gynecol Cancer, 17, 61-7. https://doi.org/10.1111/j.1525-1438.2006.00753.x
- Vergote I, Trope CG, Amant F, et al (2010). Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. N Engl J Med, 363, 943-53. https://doi.org/10.1056/NEJMoa0908806
- Webb PM, Purdie DM, Grover S, et al (2004). Symptoms and diagnosis of borderline, early and advanced epithelial ovarian cancer. Gynecol Oncol, 92, 232-9. https://doi.org/10.1016/j.ygyno.2003.09.005
- Yurkovetsky Z, Skates S, Lomakin A, et al (2010). Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol, 28, 2159-66. https://doi.org/10.1200/JCO.2008.19.2484
Cited by
- Intra-Peritoneal Cisplatin Combined with Intravenous Paclitaxel in Optimally Debulked Stage 3 Ovarian Cancer Patients: An Izmir Oncology Group Study vol.15, pp.15, 2014, https://doi.org/10.7314/APJCP.2014.15.15.6165
- Is Target Oriented Surgery Sufficient with Borderline Ovarian Tumors? - Role of Accompanying Pathologies vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6749
- Roles of Neutrophil/Lymphocyte and Platelet/Lymphocyte Ratios in the Early Diagnosis of Malignant Ovarian Masses vol.15, pp.16, 2014, https://doi.org/10.7314/APJCP.2014.15.16.6881
- Role of a Risk of Malignancy Index in Clinical Approaches to Adnexal Masses vol.15, pp.18, 2014, https://doi.org/10.7314/APJCP.2014.15.18.7793
- Level and Evaluation of Tumor Marker CA-125 in Ovarian Cancer Patients in Khyber Pakhtunkhwa, Pakistan vol.16, pp.1, 2015, https://doi.org/10.7314/APJCP.2015.16.1.185
- Improved Diagnostic Accuracy in Characterization of Adnexal Masses by Detection of Choline Peak Using 1H MR Spectroscopy in Comparison to Internal Reference at 3 Tesla vol.16, pp.12, 2015, https://doi.org/10.7314/APJCP.2015.16.12.5085
- Differentiation of Benign from Malignant Adnexal Masses by Functional 3 Tesla MRI Techniques: Diffusion-Weighted Imaging and Time-Intensity Curves of Dynamic Contrast-Enhanced MRI vol.16, pp.8, 2015, https://doi.org/10.7314/APJCP.2015.16.8.3407
- Predictive Value of Malignancy Risk Indices for Ovarian Masses in Premenopausal and Postmenopausal Women vol.17, pp.4, 2016, https://doi.org/10.7314/APJCP.2016.17.4.2177
- Individualized Treatment of Patients With Early-Stage Epithelial Ovarian Cancer After Incomplete Initial Surgery vol.26, pp.1, 2016, https://doi.org/10.1097/IGC.0000000000000583
- Can Replacing CA125 with HE4 in Risk of Malignancy Indices 1–4 Improve Diagnostic Performance in the Presurgical Assessment of Adnexal Tumors? vol.2017, pp.2314-6141, 2017, https://doi.org/10.1155/2017/6712376